CX Institutional bought a new position in Baxter International Inc (NYSE:BAX) in the third quarter, according to its most recent disclosure with the SEC. The firm bought 984 shares of the medical instruments supplier’s stock, valued at approximately $86,000.
Other institutional investors and hedge funds also recently modified their holdings of the company. Weaver Consulting Group acquired a new stake in shares of Baxter International during the 1st quarter worth about $25,000. Personal Wealth Partners acquired a new stake in shares of Baxter International during the 2nd quarter worth about $29,000. TRUE Private Wealth Advisors acquired a new stake in shares of Baxter International during the 2nd quarter worth about $29,000. Old North State Trust LLC acquired a new stake in shares of Baxter International during the 3rd quarter worth about $31,000. Finally, Evolution Wealth Advisors LLC acquired a new stake in shares of Baxter International during the 2nd quarter worth about $32,000. 83.44% of the stock is owned by institutional investors and hedge funds.
Shares of Baxter International stock opened at $88.03 on Friday. The business has a 50-day moving average of $87.00 and a 200 day moving average of $81.69. Baxter International Inc has a 12 month low of $61.05 and a 12 month high of $89.93. The stock has a market capitalization of $44.37 billion, a price-to-earnings ratio of 26.90, a price-to-earnings-growth ratio of 2.01 and a beta of 0.99. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.78 and a quick ratio of 2.10.
The company also recently announced a quarterly dividend, which was paid on Tuesday, October 1st. Investors of record on Friday, August 30th were issued a dividend of $0.22 per share. This represents a $0.88 dividend on an annualized basis and a yield of 1.00%. The ex-dividend date was Thursday, August 29th. Baxter International’s dividend payout ratio (DPR) is 28.85%.
A number of brokerages recently issued reports on BAX. Zacks Investment Research raised Baxter International from a “hold” rating to a “buy” rating and set a $86.00 price objective for the company in a research report on Friday, June 21st. Piper Jaffray Companies reissued a “buy” rating on shares of Baxter International in a research report on Tuesday, September 10th. Credit Suisse Group raised their price objective on Baxter International from $84.00 to $95.00 and gave the stock an “outperform” rating in a research report on Friday, July 26th. JPMorgan Chase & Co. set a $94.00 price objective on Baxter International and gave the stock a “buy” rating in a research report on Tuesday. Finally, Royal Bank of Canada set a $87.00 price objective on Baxter International and gave the stock a “hold” rating in a research report on Friday, July 26th. Five investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Baxter International has an average rating of “Buy” and an average price target of $85.67.
In related news, SVP Jacqueline Kunzler sold 5,934 shares of the firm’s stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $88.12, for a total transaction of $522,904.08. Following the completion of the transaction, the senior vice president now directly owns 3,089 shares in the company, valued at approximately $272,202.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director James R. Gavin III sold 7,950 shares of Baxter International stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $87.63, for a total value of $696,658.50. Following the completion of the transaction, the director now owns 40,932 shares of the company’s stock, valued at approximately $3,586,871.16. The disclosure for this sale can be found here. Insiders have sold a total of 14,064 shares of company stock valued at $1,235,359 over the last 90 days. 0.70% of the stock is currently owned by company insiders.
Baxter International Company Profile
Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.
Further Reading: What is the CBOE Russell 2000® Volatility Index?
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.